Vaccine clinical trial

HVTN 106

Status: Completed
Number of volunteers: 105
Lenght of the study: 14
months
​​​​​​

A phase I randomized, double-blind, placebo controlled clinical trial to evaluate the safety and immunogenicity of 3 different HIV-1 DNA priming regimens (Nat-B env, CON-S env, and Mosaic env) with MVA-CMDR boosts in healthy, HIV-1-uninfected adults

​​​​​​​The aim of this phase I clinical trial is to evaluate the safety and tolerability of the HIV-1 recombinant env DNA primes followed by recombinant MVA boosts.

The goal is to compare the 3 primary immunization regimens (groups 1,2 and 3) for their effect on T cell responses.

105 healthy, HIV-1-uninfected volunteers aged 18-50 years old, will be enrolled at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, for 14 months. A total of 15 visits are planned during the study, 5 immunization visits and 10 follow-up visits including blood sampling.

For further information on this study, please contact us by phone +41 21 314 1160 / +41 21 314 1163

Contact

Division of Immunology and Allergy
Monday to Friday: 8 am - 6 pm
Vaccine and Immunotherapy Center
1011 Lausanne, Suisse
Tél. +41 21 314 1160
Tél. +41 21 314 1163
Fax +41 21 314 1161
 Dernière mise à jour le 28/06/2019 à 08:09